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A functional IFN-λ4-generating 
DNA polymorphism could protect 
older asthmatic women from 
aeroallergen sensitization and 
associate with clinical features of 
asthma
Sreedhar Chinnaswamy1,7, Aleksandra Wardzynska2, Malgorzata Pawelczyk2, Joanna 
Makowska2,3, Tea Skaaby  4, Josep M. Mercader5, Tarunveer S. Ahluwalia  6, Niels Grarup  11, 
Marta Guindo-Martinez5, Hans Bisgaard6, David Torrents5,10, Allan Linneberg  4,8,9, Klaus 
Bønnelykke6 & Marek L. Kowalski2,7
Lambda interferons (IFNLs) have immunomodulatory functions at epithelial barrier surfaces. IFN-λ4, 
a recent member of this family is expressed only in a subset of the population due to a frameshift-
causing DNA polymorphism rs368234815. We examined the association of this polymorphism with 
atopy (aeroallergen sensitization) and asthma in a Polish hospital-based case-control cohort comprising 
of well-characterized adult asthmatics (n = 326) and healthy controls (n = 111). In the combined 
cohort, we saw no association of the polymorphism with asthma and/or atopy. However, the IFN-
λ4-generating ΔG allele protected older asthmatic women (>50 yr of age) from atopic sensitization. 
Further, ΔG allele significantly associated with features of less-severe asthma including bronchodilator 
response and corticosteroid usage in older women in this Polish cohort. We tested the association 
of related IFNL locus polymorphisms (rs12979860 and rs8099917) with atopy, allergic rhinitis and 
presence/absence of asthma in three population-based cohorts from Europe, but saw no significant 
association of the polymorphisms with any of the phenotypes in older women. The polymorphisms 
associated marginally with lower occurrence of asthma in men/older men after meta-analysis of data 
from all cohorts. Functional and well-designed replication studies may reveal the true positive nature of 
these results.
Type III interferons (IFNs) or IFN-λs (or IFNLs) are known to play critical roles in innate and adaptive immune 
responses to viral infections. Several recent reports have implicated IFN-λs as the ‘guardians’ of the epithelial 
1National Institute of Biomedical Genomics, PO:N.S.S, Kalyani, 741251, West Bengal, India. 2Dept. of Immunology, 
Rheumatology & Allergy, Medical University of Lodz, Lodz, 92-213, Poland. 3Department of Rheumatology, 
Medical University of Lodz, 92-003, Lodz, Poland. 4Research Centre for Prevention and Health, the Capital Region 
of Denmark, Copenhagen, Denmark. 5Barcelona Supercomputing Center (BSC). Joint BSC-CRG-IRB Research 
Program in Computational Biology, 08034, Barcelona, Spain. 6COPSAC, Copenhagen Prospective Studies on 
Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. 7Chair of 
Clinical Immunology and Microbiology, Healthy Aging Research Center, Medical University of Lodz, 251 Pomorska 
Str, 92-213, Lodz, Poland. 8Department of Clinical Experimental Research, Rigshospitalet, Denmark. 9Department 
of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 
10Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. 11The Novo Nordisk Foundation Center 
for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2100, Copenhagen, 
Denmark. Correspondence and requests for materials should be addressed to S.C. (email: sc2@nibmg.ac.in)
Received: 14 November 2016
Accepted: 10 August 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 10500  | DOI:10.1038/s41598-017-10467-y
barrier surfaces that encompass large regions of the human body that include respiratory, gastrointestinal and 
reproductive tracts1. Single nucleotide polymorphisms (SNPs) at the IFNL locus on human chromosome 19 were 
discovered a few years ago to be associated with chronic hepatitis C virus (HCV) infections2–4. These SNPs, dis-
covered initially by genome-wide association studies (GWAS) to be associated with treatment-induced clearance 
of HCV, got widely validated and were subsequently found to be associated with different human diseases, both 
viral and non-viral in origin (reviewed in 5). The immunomodulatory role of IFN-λs is thought to be the molecu-
lar mechanism behind these associations5. Among the different SNPs at the IFNL locus, that are in strong linkage 
disequilibrium (LD) in most populations, a dinucleotide polymorphism rs368234815 (TT/ΔG) has emerged as 
the ‘causal’ variant5, 6. The ΔG allele of the variant causes a shift in the open reading frame of the IFNL4 gene, giv-
ing rise to a new IFN-λ called IFN-λ46. IFN-λ4 has undergone purifying selection during human evolution with 
highest frequency of the functional IFN-λ4-generating ΔG allele in the African population (0.78) and lowest in 
the East Asian population (0.06)6, 7; 50-60% of the European population carries at least one copy of the functional 
gene8. IFN-λ4 is a potent antiviral cytokine with structural and functional similarity to IFN-λ1, 2 and 38, 9. The 
latter are known to modulate adaptive immunity favoring a Th1 predominant response10–12. Even though there 
is no direct evidence yet, IFN-λ4 is also expected to participate in shaping and maintaining innate and adaptive 
immune responses at the epithelial lining of the respiratory tract owing to its similarities with other IFN-λs. 
The interactions of IFN-λs with the newly discovered innate lymphoid cells (ILCs)13 are likely to hold the key to 
improving our understanding of diseases like allergy and asthma5.
Atopy, defined as increased predisposition to generate specific IgE to common allergens, and diagnosed in 
an individual subject by presence of aeroallergen sensitization, may lead to Th2-driven immune response to 
harmless allergens resulting in development of allergic diseases including asthma. Exacerbations in asthma are 
commonly associated with respiratory virus infections, and impaired innate immune responses have been doc-
umented in asthma patients14, 15. Since both the development of atopic predisposition and asthma exacerbations 
may involve respiratory viral infections, we undertook this study with the hypothesis that these complex disorders 
are influenced by the IFN-λ4-generating polymorphism.
Results and Discussion
ΔG allele of rs368234815 protects older women asthmatics from atopy in a Polish hospi-
tal-based case-control cohort. We used a Polish discovery cohort that included 326 well-characterized 
adult bronchial asthmatics recruited from the university asthma clinic, medical university of Lodz. Cases were 
heterogeneous with respect to the disease control and severity. Controls comprised of 111 volunteers without 
any chronic respiratory disorders representing a sample of general population. Information on atopic sensitiza-
tion (determined by skin prick test or SPT to a panel of inhalant allergens) was available for 384 subjects (273 
asthmatics and 111 controls). The patient and control group characteristics are shown in Table 1. Owing to its 
functional nature we chose and genotyped the functional IFN-λ4-generating polymorphism rs368234815 in this 
cohort. Power calculations showed that we had enough sample size to give >80% power (at a significance level of 
p = 0.05) to detect an effect size of 1.55 and 1.6 in atopy and asthma, respectively.
The Minor Allele Frequency (MAF) in the combined population of controls and asthma patients (cases) was 
0.34; the distribution of genotypes was: 38%, 53%, 9% and 44%, 44%, 12% for TT/TT, TT/ ΔG and ΔG/ΔG in 
controls and cases respectively. Both controls and cases were in Hardy-Weinberg equilibrium (HWE) (P > 0.05) 
either individually or as a combined group. In the combined group analysis there was no association of the pol-
ymorphism with asthma or atopy under either dominant or recessive models of inheritance (Table 2). However, 
by using log-linear regression we observed statistically significant interactions between the polymorphism, atopy, 
age and gender (interactions up to three factors; polymorphism, age and gender p = 0.037; polymorphism, gender 
and atopy p = 0.035). To dissect these interactions further, we stratified our atopy data into several groups based 
on age and gender (Table 3) and applied bonferroni correction to avoid false positives arising due to multiple 
testing. Since our study group had a majority of women (Table 1), we chose 50 years as a divider of age in the 
combined cohort for our stratified analysis as it is also the age of attainment of menopause16 (overall median age 
at natural menopause in Poland is 51.25 years17,). Only among the >50 yr sub-group of women (older women) we 
saw a significant association of the polymorphism with atopy after multiple testing correction under a dominant 
model of inheritance for the minor allele. The ΔG allele conferred protection from allergic sensitization in older 
asthmatic women. The significance of association was retained in both the asthmatic older women and in the 
combined group of asthmatic and control older women, but not in the control older women’s sub-group when 
tested alone, in both univariate and multivariate analysis (Table 4).
Even though the association was significant in the older women’s sub-group, small sample sizes may have pre-
vented us from appreciating the effect of the polymorphism on atopy in the remaining sub-groups. In addition, a 
validation of the observed effect on the older women’s sub-group is required from other populations and/or geo-
graphical regions. To examine this and to investigate the association of the IFNL locus SNPs with atopy, asthma 
and related illnesses, we used data from the Genetic Epidemiology Research on Adult Health and Aging (GERA, 
dbGaP Study Accession: phs000674.v1.p1)18, Inter9919, Health200620 and COPSAC21, 22 cohorts. The characteris-
tics of the different study cohorts are briefly described in Table 5. The GERA cohort consisted of predominantly 
older participants (average age 63 yr, range 18 to over 100 yr) and hence all participants in this cohort were con-
sidered as being older (>50 yr) for analysis.
Genotype information for a related IFNL polymorphism rs129798605 was available in the other European 
cohorts, hence, we tested the association of atopy with rs12979860 in the Inter99, Health2006 and the COPSAC 
cohorts in four different sub-groups based on both age and gender and did a meta-analysis using a random-effects 
model on all the cohorts where atopy data was available including the Polish cohort (Fig. 1). Even though, the 
Polish cohort tested for rs368234815 and the other cohorts for rs12979860 the data could be compared since a 
strong LD (r2 = 0.98) between them in the European population has been recorded6; furthermore, the MAFs in 
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the cohorts were similar (Table 5). Moreover, recent data shows that the SNP rs12979860 is the ‘best tag-SNP’ for 
the functional polymorphism rs368234815 due to a common underlying linkage structure at the IFNL locus23. 
The results show that we failed to replicate our findings from the older women’s sub-group of the Polish cohort, 
in other cohorts (Fig. 1). Further, except for a nominal association (p = 0.04) with an additive genetic model in 
the COPSAC younger men’s cohort no other sub-group in any of the remaining cohorts showed any significant 
association with atopy (Fig. 1). The older women’s and younger men’s sub-groups had significant heterogeneity in 
the effect of the polymorphisms (p = 0.008 and p = 0.028 respectively) between the different cohorts and no sig-
nificant association was seen after meta-analysis. Even in the other sub-groups where there was no significant het-
erogeneity between the studies, no significant effect of the polymorphism on atopy was noted in the meta-analysis 
(Fig. 1). Similar results were seen using the fixed-effect model (Suppl. Figure 1)
asthma, N = 326 controls, N = 111
age, years* 59.2 ± 15.9 (18–94) 52.3 ± 18.3 (24–81)
gender, women, n (%) 201 (61.7%) 72 (64.9%)
Men > 50 yr average age (range)/n 67.3 ± 9.8 (50–87)/92 65.2 ± 9.7 (50–80)/18
Men < 50 yr average age (range)/n 34.2 ± 7.5 (18–48)/33 32.9 ± 5.9 (24–48)/21
Women > 50 yr average age (range)/n 67.3 ± 9.3 (50–94)/144 67 ± 7.2 (51–81)/47
Women < 50 yr average age (range)/n* 40 ± 6.6 (24–49)/57 34.1 ± 6.5 (26–49)/25
Atopy, n/N tested (%)* 141/273 (51.6%) 39/111 (35.1%)
FEV1% pred. 75.3 ± 24.1 (17.5–129.5) –
FEV1%/FVC 68 ± 13.1 (25.6–99.4) –
ACT, points 17.8 ± 5.5(4–25) –
FeNO (ppb) 30.6 ± 17.8 (2–184) –
Asthma control (according to GINA 2016)
  Controlled, n (%) 72 (22%) –
  partly controlled, n (%) 96 (30%) –
  Uncontrolled, n (%) 156 (48%) –
Current asthma treatment
  ICS, n (%) 240 (73.6%) –
  low dose**, n (%) 28 (8.6%)
  medium dose**, n (%) 120 (36.8%)
  high dose dose**, n (%) 92 (28.2%)
  Oral steroids, n (%) 23 (7.1%) –
  LABA, n (%) 197 (60.4%)
  Leukotriene antagonists, n (%) 64 (19.6%)
  at least 1 exacerbation/last year, n (%) 170 (52.1%) –
Table 1. Characteristics of the study subjects in the Polish cohort. Values are presented as arithmetic 
means + SD, (range); *statistically significant difference between groups, p < 0.05; values shown in bold; 
**according to GINA 2016.
Genotype (n, %)
Dominant model (TT/
ΔG + ΔG/ΔG) vs TT/TT
Recessive model ΔG/ΔG 
vs (TT/ΔG + TT/TT)
TT/TT TT/ΔG ΔG/ΔG Total OR (95% CI); p-value OR (95% CI); p-value
Asthma 145, 44.5 142, 43.5 39, 12 326, 100
0.75 (0.48–1.18); 0.26 1.37 (0.66–2.85); 0.48
Controls 42, 37.8 59, 53.2 10, 9 111, 100
Atopy + 81, 45 80, 44.4 19, 10.6 180, 100
0.72 (0.48–1.09); 0.14 0.84 (0.44–1.59); 0.63
Atopy − 76, 37.2 103, 50.5 25, 12.3 204, 100
Asthma*
Atopy+ 64, 45.4 61, 43.3 16, 11.3 141, 100
0.75 (0.46–1.22); 0.27 0.81 (0.39–1.66); 0.58
Atopy− 51, 38.6 63, 47.7 18, 13.7 132, 100
Controls
Atopy+ 17, 43.6 19, 48.7 3, 7.7 39, 100
0.68 (0.31–1.52); 0.41 0.77 (0.18–3.17); 1
Atopy− 25, 34.7 40, 55.5 7, 9.7 72, 100
Table 2. Association of the functional IFN-λ4-generating polymorphism rs368234815 with asthma and atopy 
in the Polish cohort. *Skin prick test was not carried out for 53 asthmatics as they were under treatment with 
antihistamines, antidepressants or there were other contraindications.
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Next, we tested if the IFNL polymorphisms associated with presence of asthma in different cohorts, again by 
stratification analysis based on both age and gender and by meta-analysis using random-effects model (Fig. 2). 
No significant heterogeneity in the effect between different cohorts in the sub-groups was noted. None of the 
sub-groups from any of the cohorts including the Polish cohort, showed any significant association with asthma. 
Interestingly, the older men’s sub-group showed a significant effect of the polymorphism(s) on presence/absence 
of asthma after meta-analysis. The minor allele (which gives rise to/linked to the allele that can express a func-
tional IFN-λ4) had a protective effect on asthma in the older men. However, given the large sample size involved 
in the GERA cohort such low significance of association suggests a very small effect on the phenotype and/or 
phenotypic heterogeneity. Similar results were seen with a fixed-effects model (Suppl. Figure 2).
Since the GERA cohort also included data on allergic rhinitis (AR) we tested if rs12979860 and another related 
SNP rs8099917 associated with it (Table 6) in gender-stratified sub-groups. No significant association of either 
SNP with AR was evident in males or females.
We extended our meta-analysis to see if the IFNL polymorphisms associated with atopy and asthma in: 1) all 
individuals irrespective of age and gender and 2) gender-specific and age-specific strata from the other European 
cohorts. All the cohorts included for this meta-analysis had the same SNP rs12979860 either directly genotyped 
or imputed and the MAFs in each of the cohorts were similar (Table 5). All studies were homogenous for the effect 
of the polymorphism except for the all men’s group when testing for atopy (Fig. 3A). A significant association with 
asthma was detected only in the sub-group of ‘all men’ (Fig. 3B) similar to the effect seen for asthma in the older 
men’s sub-group in Fig. 2. Since, we did not have enough participants in the younger men’s group compared to the 
large sample size of older men from the GERA cohort, the modifying effect of age, if any, on the association of the 
polymorphism with asthma could not be reliably tested.
In conclusion, the results from the Polish cohort on the association of the polymorphism(s) with atopy could 
not be replicated in other European cohorts while a significant association of the polymorphism(s) was seen with 
asthma in men/older men when data was meta-analyzed. In instances where a significant association was seen, 
the minor allele showed a protective phenotype.
Functional IFN-λ4-generating ΔG allele associates with less severe features of asthma in the 
older women’s sub-group of the Polish cohort. We refocused our interest on the Polish older wom-
en’s sub-group where we saw a significant association of the IFN-λ4-generating polymorphism with atopy. We 
observed that this sub-group which comprised of both asthmatic and control older women had a majority (75%) 
of asthmatics (Table 4). Therefore we were interested to examine if any of the clinical features of asthma are 
also associated with the polymorphism (Table 7 and Table 8) in the older asthmatic women. We saw a signif-
icant association between the polymorphism and positive bronchial reversibility (or bronchodilator response, 
BDR) test and usage of corticosteroids (CS) for treatment (Table 8). Older women with at least one copy of the 
IFN-λ4-generating ΔG allele were less likely to be treated with iCS (inhaled CS) (OR = 0.35) and oCS (oral 
CS) (OR = 0.16) but were more likely to show a positive BDR (OR = 2.58) by univariate analysis. To test for 
Group Sub-group N OR (95% CI) p-value p-value*
All
All ages 384 0.72 (0.48–1.09) 0.123 1
>50 yr 261 0.51 (0.31–0.85) 0.009 0.081
<50 yr 123 1.26 (0.59–2.68) 0.548 1
Men
All ages 145 1.28 (0.66–2.47) 0.458 1
>50 yr 94 0.81 (0.35–1.88) 0.394 1
<50 yr 51 1.53 (0.41–5.73) — —
Women
All ages 239 0.51 (0.3–0.86) 0.012 0.108
>50 yr 167 0.37 (0.19–0.72) 0.002 0.018
<50 yr 72 1.01 (0.39–2.62) 1 1
Table 3. The ΔG allele of rs368234815 associates with protection from atopy in older women in the Polish 
cohort. *After bonferroni correction; A dominant model of inheritance for the minor allele (TT/ΔG + ΔG/ΔG 
vs TT/TT) was used to compute OR.
Group
Dominant Model (TT/ΔG + ΔG/ΔG) vs TT/TT
OR (crude) 95% CI p OR (adjusted)* 95% CI p
1Women (Asthma) > 50 yr N = 128; atopy, n = 55 0.398 0.188–0.841 0.016 0.402 0.184–0.877 0.021
2Women (Controls) > 50 yr N = 39; atopy, n = 11 0.400 0.098–1.631 0.202 0.366 0.083–1.605 0.171
3Women (Asthma + Controls) > 50 yr N = 167; 
atopy, n = 66 0.379 0.198–0.724 0.003 0.409 0.208–0.803 0.016
Table 4. Association of the functional IFN-λ4-generating polymorphism rs368234815 with atopy in older 
women in the Polish cohort. *1, *2 for age; *3 for asthma status and age. A dominant model of inheritance is 
shown with significant results (p < 0.05) in bold. No significant association under any group/sub/group was 
seen using the recessive model of inheritance.
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confounders we carried out multivariate regression analysis and found that atopy could be partly mediating the 
association between the polymorphism and BDR (Table 8).
In summary, results from the Polish cohort demonstrated that IFN-λ4-generating ΔG allele protected a sub-
population of asthmatic patients, specifically older women, from allergic sensitization. The IFN-λ4-generating 
ΔG allele also associates with less inhaled and oral CS usage, suggesting that it may be related with lesser disease 
severity in this group of severe asthmatics (78% of overall cases had either partially controlled or uncontrolled 
asthma, Table 1). Further, it goes on to suggest that the ΔG allele carriers possibly had reduced airway inflamma-
tion compared to the pseudogenizing TT/TT genotype carriers.
Inherent differences between the discovery and replication cohorts may have been responsible 
for non-replication of our results from the Polish cohort. The association of IFNL polymorphism 
with atopy in the Polish older women’s cohort survived correction for multiple testing that was carried out as a 
measure to negate the limitation of post-hoc analysis of data (Table 3). Further, the results from the Polish study 
are not due to a ‘cohort effect’ since the association of the polymorphism with atopy is within the older women’s 
‘cohort’ and not between an older and a younger ‘cohort’. The association of the polymorphism in older women 
was not just with atopy but also translated to association with some important determinants of severity of asthma 
like BDR and CS usage. Even though we did not carry out multiple testing correction for our association tests 
with the polymorphism and clinical features of asthma (Table 8) we feel the phenotypes are not independent of 
the atopic sensitization phenotype that we identified during our initial analysis (Tables 3 and 4), and therefore 
less likely to be false positives. For example, atopy-related eosinophilic inflammation and increased CS usage 
frequency among patients may be correlated24; this is apart from the fact that atopy was a confounder with the 
association involving bronchial reversibility tests (Table 8). Therefore the results from the Polish study regarding 
association of the polymorphism with atopy and clinical features of asthma in older women, seem to be consistent 
with each other.
It is important to analyze and interpret our results from the Polish study in the context that they were not rep-
licated in other cohorts of the European population. It should be noted that the replication study had several lim-
itations. Firstly, the findings we made in the Polish cohort were from a hospital-based case-control design while 
all the three replication cohorts (except COPSAC cohort) were population-based (Table 5). Secondly, 72% of the 
Polish cohort (among the 384 subjects with information on atopy) were asthma cases and specifically the older 
women’s sub-group in this cohort had substantially more (75%) asthmatics than controls while the replication 
cohorts had 16% asthmatics among older men and women in GERA cohort (10% in AR-negative controls and 
34% in AR-positives; AR-negative controls were 77% and AR -positive were 33% in the cohort); 9.6% and 11.6% 
of older women had asthma in the Inter99 and Heath2006 cohorts respectively. It is possible that the association 
with atopy in the Polish cohort had an underlying link with asthma that could not be accounted for in the repli-
cation study. In support of this, significance of association decreased when data was adjusted for asthma status 
in the older women’s sub-group in the Polish study (Table 4). Thirdly, the Polish cohort was enriched with severe 
asthmatics (22% controlled, 30% partly controlled and 48% uncontrolled according to GINA 2016; up to 65% of 
patients were in medium or high dose iCS; 60% were on long acting β-agonists; Table 1) while this information 
was not available for the replication cohorts. Fourthly, similar methods were not used to test for the phenotypes 
in all the cohorts (Ex. SPT in the Polish cohort and serum specific IgE in the Danish cohorts to test atopy). While 
in the discovery cohort that had a hospital-based case-control design, we saw a significant association of the 
Cohort Type Genotype* tested MAF
Phenotype data 
available
Total no. of 
participants Ref. Remarks
Inter 99 Population-based rs12979860 (g) 0.34 Atopy Asthma 5341 19
Atopy 
determined 
by serum 
specific IgE; 
self-reported 
doctor-
diagnosed 
asthma
Health 2006 Population-based rs12979860 (g) 0.34 Atopy Asthma 3134 20
COPSAC Case-control (hospital-based; parents of asthmatic children) rs12979860 (g) 0.30 Atopy Asthma 551 21
All 
participants 
below 50 yr 
of age; Atopy 
determined by 
serum specific 
IgE
GERA Population-based rs12979860 (i); rs8099917 (i) 0.32; 0.19
Allergic rhinitis, 
Asthma 56637 18
Average age 
63 yr (range18 
to over 100 yr)
Polish Hospital-based Case-control rs368234815 (g) 0.34 Atopy, asthma 437 —
Atopy 
determined by 
SPT; asthma 
treated and 
monitored
Table 5. Characteristics of the different study cohorts used in the study. *g-genotyped; i-imputed; MAF-minor 
allele frequency.
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polymorphism with atopy (in an asthma-enriched background) and severe asthma features in older women, in 
the replication study we tested for association with atopy, allergic rhinitis and presence/absence of asthma in a 
population-based cohort. These discrepancies in endpoint phenotypes and the intrinsic differences in the compo-
sition of the Polish and the replication cohorts may have led to non-replication of the findings.
Our findings from the Polish cohort need to be further validated in well-designed replication studies and func-
tional studies. It is likely that the functional IFN-λ4-generating dinucleotide variant rs368234815 may associate 
with a specific endotype of severe asthma in older patients. It is possible that a sustained course of inflammation of 
the airways that happens in older asthmatics, likely in response to viral infections over a period of time, will lead 
to an environment conducive for the penetrance of the genetic effect of IFNL variants in asthma. Since the Polish 
cohort had >60% women asthma patients and was enriched with older women (Table 1) we saw strong associ-
ation in the older women’s sub-group (Fig. 1 and Table 3). We hypothesize that presence of IFN-λ4-generating 
ΔG allele may be beneficial for an elderly female asthma patient by protecting the airways from increased inflam-
mation associated with virus-induced asthma exacerbations. Although, no direct association of the allele with 
history of asthma exacerbations or hospitalizations was revealed (data not shown), it should be noted that the 
Polish asthma cohort represented a group of difficult-to-control asthmatics (only 22% had well-controlled disease 
according to GINA criteria; Table 1). Along these lines, association of the allele with the presence of acute airway 
reversibility in response to inhaled beta2- agonists may indirectly reflect less severity of the disease and/or lower 
airway remodeling in those patients that carry an IFN-λ4-generating ΔG allele. It remains to be established if 
the effect of the functional IFN-λ4-generating variant on asthma control and severity is also valid in older men. 
We did see a protective effect of the minor allele rs12979860 (which tags the IFN-λ4-generating allele) against 
asthma in older men/all men after meta-analysis of data (Figs 2 and 3). However, the significance of association 
is low given the large sample size tested.
Figure 1. Forest plots showing association of IFNL polymorphisms and atopy in sub-groups based on age and 
gender in different cohorts. The tag-SNP rs12979860 was used in all other cohorts except the Polish cohort that 
tested for functional polymorphism rs368234815. A dominant model of inheritance for the minor allele (Ex. 
TT/ ΔG + ΔG/ ΔG vs TT/TT for rs368234815) was used in all cohorts except in the COPSAC cohort that 
used an additive model to obtain Odds Ratios (OR) shown as a forest plot. p-value < 0.05 was considered as 
significant and is in bold. For stratification based on age 50 yr was used as a cut-off mark. Het.-heterogeneity.
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Further, it remains to be verified if rs368234815 is the functional variant behind this association in atopy/
asthma or other IFNL SNPs may also contribute to the phenotype by altering the levels of IFN-λ3 expression 
similar to recent observations in hepatic inflammation and fibrosis25. Future studies aimed at understanding the 
functional role of IFN-λ4 in regulating inflammation of the airways are required to understand the mechanism 
behind the association that we identified in the Polish study. Alternately, this finding could be a false positive 
Figure 2. Forest plots showing association of IFNL polymorphisms and asthma in sub-groups based on age and 
gender in different cohorts. The polymorphisms tested are similar to Fig. 1. A dominant model of inheritance 
for the minor allele (Ex. TT/ ΔG + ΔG/ ΔG vs TT/TT for rs368234815) was used in all cohorts to obtain Odds 
Ratios (OR) shown as a forest plot. p-value < 0.05 was considered as significant and is in bold. Meta-analysis 
was performed using a random-effects model.  For stratification based on age 50 yr was used as a cut-off mark. 
Het.-heterogeneity.
GERA cohort Allergic Rhinitis
SNP Model tested
Group/sub-
group
N, total; n, cases; 
n, controls
OR (95% 
CI) p-value
rs12979860 (C/T)
Dominant 
(CT + TT vs 
CC)
All 56637; 13936; 42701
1.01 (0.97, 
1.05) 0.62
Men 22716; 4859; 17857
1 (0.94, 
1.07) 0.96
Women 33921; 9077; 24844
1.02 (0.97, 
1.07) 0.51
rs8099917 (C/T)
Dominant 
(TG + GG vs 
TT)
All Same as above 1 (0.96, 1.04) 0.91
Men 1 (0.94, 1.07) 0.95
Women 1 (0.95, 1.05) 0.93
Table 6. Association of IFNL locus SNPs with allergic rhinitis in the GERA cohort. GERA cohort consisted of 
predominantly older participants (average age 63 yr, range 18 to over 100 yr).
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result, which also has to be confirmed by doing a well-designed replication study first in another Polish cohort 
and later in other populations. Nevertheless, our comprehensive analysis with sufficiently large sample sizes has 
established that an important candidate gene locus consisting of the immunomodulatory type III IFNs does not 
associate with atopy and AR in the general population (Fig. 3A and Table 6). The association could be more subtle 
and with specific endotypes related to inflammation of the airways in asthma. The protection to asthma seen in 
men/older men (Figs 2 and 3) is nominal and further studies can aim at validation of this result in more specific 
endotypes based on severity of asthma. A fully functional IFN-λ4 may be associated with protecting the airways 
from inflammation in certain endotype(s) of the disease, specifically in older asthmatics. While further studies are 
needed to understand this association, whether these endotypes are a result of virus-induced stimuli, also remains 
to be examined. A previous report documented a strong positive association of allergy26, interestingly more pro-
nounced in females than males, with the minor allele of rs12979860 (which is in strong LD with rs3682348156) in 
a pediatric cohort. Our results from the Polish cohort, in contrast, show that the IFN-λ4-generating ΔG minor 
Figure 3. Forest plots showing the summary estimates obtained from all the participants or from different 
groups based on age and gender after meta-analysis of data from different cohorts for (A) atopy and (B) asthma. 
The association was tested with atopy or asthma and rs12979860 using a dominant model for the minor allele 
(CT + TT vs CC) in all cohorts except for atopy in the COPSAC cohort where an additive model (for minor 
allele T) was used. The cohorts included in each of the meta-analysis and the effect heterogeneity between 
different cohorts is shown. p-value < 0.05 was considered as significant and is in bold. Meta-analysis was 
performed using a random-effects model, while the results were similar using the fixed-effects model too.   
For stratification based on age 50 yr was used as a cut-off mark. Het.-heterogeneity.
Variable
Genotype
p-valueTT/TT TT/ΔG + ΔG/ΔG
Age (years) 66 + /− 8,2 68,3 ± 9,9 0.156
age at asthma diagnosis (years) 47,3 ± 15,2 50,5 ± 18 0.253
asthma duration (years) 18,8 ± 14,4 18,6 ± 17,6 0.954
ACT sum (points) 17 ± 5,2 17,5 ± 5,7 0.574
MRC (points) 2,7 ± 0,9 2,6 ± 1 0.471
FeNO (ppb) 32,4 ± 27 24,7 ± 15,1 0.098
BMI 28,6 ± 5,3 27,5 ± 4,1 0.199
FEV1% pred. 76,4 ± 25 70,7 ± 25,4 0.189
FVC% pred. 89,8 ± 21,2 85,9 ± 25,4 0.345
FEV1%/FVC% 68,5 ± 14,5 67 ± 12,5 0.507
Table 7. Clinical features of asthma in older women according to rs368234815 genotypes in the Polish cohort. 
Values are presented as arithmetic means ± SD.
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allele may protect older women from atopy rather than contributing to it. The reasons for this paradox remain 
to be investigated but may likely involve complex epistatic effects mediated by other innate or adaptive immu-
nity genes and age-dependent changes in Th1/Th2 balance during the transition from infancy to adulthood. 
Interestingly, age and gender are known to interact and influence the association of rs12979860 with another 
inflammatory condition of Th2-origin, fibrosis, in chronic HCV infections27.
Material and Methods
Polish study. Both the controls (N = 111) and asthmatics (N = 326) belonged to same ethnicity (local Polish 
population) and geography (residents of central Poland). Asthma control was assessed according to GINA 2016 
(global initiative for asthma) guidelines and atopy was defined as presence of a positive skin response (weal diam-
eter >3 mm) to at least one of a panel of common inhalant allergens applied as a skin-prick test (SPT). Evaluation 
also included a questionnaire, FeNO (fractional exhaled nitric oxide) measurement, spirometry and reversibility 
test with 400 µg salbutamol MDI performed in 280 patients. Genomic DNA was isolated from EDTA-treated 
whole blood samples using the Qiagen blood genomic DNA mini kit. A competitive allele-specific polymerase 
chain reaction (PCR) (KASP, LGC Genomics, UK) was used to genotype the functional IFN-λ4-generating SNP 
rs368234815; the assay was carried out in a StepOnePlus real-time PCR machine (Applied Biosystems, UK). The 
study was approved by the local Bioethics Committee (document no. RNN/121/12/KE) and all study subjects 
provided an informed written consent. All methods were carried out in accordance with relevant guidelines and 
regulations stipulated by the Medical University of Lodz and/or other relevant authorities under it. Further, the 
university granted approval for all the experimental protocols performed in this study.
Since the dominant and recessive models of inheritance have been reported previously for the IFNL SNP 
association with various diseases5, we used both these models to test for association with various phenotypes 
in our study. Statistical analyses of data included log-linear (for testing interactions between different variables) 
and logistic regression (for multivariate analysis); goodness-of-fit was tested using Pearson’s chi-square test or 
two-tailed Fischer’s exact test. All statistical analyses were performed using Statistica 12.5 PL; p-value of < 0.05 
was considered statistically significant unless specified.
Inter99 and Health2006 study. The Health2006 Study took place from 2006 to 2008 and included a ran-
dom sample of 7,931 Danish (Danish nationality and born in Denmark) men and women aged 18–69 years 
invited to participate in a health examination. The Inter99 Study is a randomised controlled trial (CT00289237, 
ClinicalTrials.gov) aiming to investigate the effects of a lifestyle intervention on cardiovascular disease 
(N = 61,301). The details of these two study cohorts on genotyping and data collection on atopy and asthma are 
described elsewhere19, 20. The Health2006 Study and the Inter99 Study were approved by the Ethics Committee 
of Copenhagen County and the Danish Data Protection Agency. All participants gave their informed consent, 
and all methods were carried out in accordance with relevant guidelines and regulations. The Health2006 and 
Inter99 datasets generated during and/or analysed during the current study are not publicly available due to eth-
ical and legal reasons since public availability may compromise participant privacy, and this would not comply 
with Danish legislation. Requests for data should be addressed to Professor Allan Linneberg. Access to data will 
be provided in accordance with the Danish Data Protection Agency.
GERA study. GERA cohort data was obtained through dbGaP under accession phs000674.v1.p1. 
The Resource for Genetic Epidemiology Research on Aging (GERA) Cohort was created by a RC2 “Grand 
Opportunity” grant that was awarded to the Kaiser Permanente Research Program on Genes, Environment, 
and Health (RPGEH) and the UCSF Institute for Human Genetics (AG036607). The RC2 project enabled 
genome-wide SNP genotyping (GWAS) to be conducted on a cohort of over 100,000 adults who are members of 
BDR iCS oCS
TT/ΔG + ΔG/
ΔG (n/N, %) 41/64, 64.1 61/83, 73.5 2/83, 2.4
TT/TT (n/N, %) 20/49, 40.8 54/61, 88.5 8/61, 13.1
OR crude 2.583 0.359 0.163
95% CI 1.203–5.55 0.142–0.907 0.033–0.8
p 0.01 0.03 0.02
OR adjusted* 4.651 0.112 0.146
95% CI 1.414–15.15 0.02–0.619 0.013–1.594
p 0.01 0.01 0.10
OR adjusted** 2.262 0.248 0.227
95% CI 0.975–5.235 0.081–0.751 0.041–1.237
p 0.05 0.01 0.08
Table 8. Association of the functional IFN-λ4-generating polymorphism rs368234815 with clinical features 
of asthma in women > 50 yr age sub-group in the Polish cohort. Dominant model of inheritance for the minor 
allele (TT/ΔG + ΔG/ΔG vs TT/TT) was tested; No significant results were seen under the recessive model. 
*OR adjusted for age, age at asthma diagnosis, FeNO, BMI, FEV1% and atopy; **OR adjusted for atopy. p < 0.05 
was considered significant and is shown in bold.
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the Kaiser Permanente Medical Care Plan, Northern California Region (KPNC), and participating in its RPGEH. 
The resulting GERA cohort is composed of 42% of males, 58% of females, and ranges in age from 18 to over 100 
years old with an average age of 63 years at the time of the RPGEH survey (2007). A subset of 62,281 subjects from 
European ancestry was quality controlled (QCed) and analyzed. A 3-step QC protocol was applied using PLINK 
and included 2 stages of SNP removal and an intermediate stage of sample exclusion. The exclusion criteria for 
genetic markers consisted on: proportion of missingness ≥0.05, HWE p-value ≤ 1 × 10–20 for all the cohort, and 
MAF <0.001. This protocol for genetic markers was performed twice, before and after sample exclusion. For 
the individuals, we considered the following exclusion criteria: gender discordance, subject relatedness (pairs 
with PI-HAT ≥ 0.125 from which we removed the individual with the highest proportion of missingness), variant 
call rates ≥0.02 and population structure showing more than 4 standard deviations within the distribution of 
the study population according to the first seven principal components. After the QC analysis, 56,637 subjects 
remained for genotype imputation and association testing.
We performed a two-stage imputation procedure, which consisted in pre-phasing the genotypes into whole 
chromosome haplotypes followed by imputation itself. The pre-phasing was performed using the SHAPEIT228 
tool, IMPUTE229 for genotype imputation and the SNPTEST (https://mathgen.stats.ox.ac.uk/genetics_software/
snptest/snptest.html#introduction) for association testing. In this work we used 1000 G Phase 3 haplotypes 
(October, 2014) as a reference panel to infer ungenotyped variants. After genotype imputation, variants with info 
score < 0.7 and MAF < 0.001 were removed. Association testing with SNPTEST tool was performed using an 
additive and dominant logistic regression model adjusting by the 7 derived principal components, age distributed 
in 14 groups and sex. Moreover, variants with HWE p.value ≤ 1 × 10−6 for controls were removed. The diagnostic 
criteria for allergic rhinitis were based on the following ICD9 codes: 477, 477.0, 477.1, 477.2, 477.8, 477.9 (https://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetPdf.cgi?id=phd004308).
COPSAC study. The Copenhagen Prospective Studies on Asthma in Childhood (COPSAC2000) is a clini-
cal study comprising 411 children with high risk of asthma born to asthmatic mothers. Information on Doctor 
diagnosed asthma was available for parents of COPSAC2000 study which was used in the current analyses. The 
COPSAC study is described in detail elsewhere21. Genotyping of parents was performed on the Illumina Infinium 
II HumanHap550 BeadChip and has been described previously22. All participants gave their informed consent. 
The Ethics Committee for Copenhagen and the Danish Data Protection Agency approved this study.
Meta-analysis. R programing using the function ‘rma’ from ‘metafor’ R package (R Core Team, 2015) was 
used. Pooled data were analysed by using a random-effects model (using DerSimonian-Laird’s method). The 
random-effects model was chosen even when effects were homogenous across cohorts since one cohort (GERA) 
had overwhelmingly large sample size compared to other cohorts and also the cohorts were not uniform in 
their characteristics (Ex. the Polish cohort was a hospital-based case-control study while the other cohorts were 
population-based). The significance of the pooled OR was determined by the z-test. Heterogeneity between stud-
ies was assessed using the Chi-squared based Cochran’s Q-test.
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